Clinical Trials Browser

Approved for marketing × enfortumab vedotin × Clear all

NCT04136808 2020-01-13

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Approved for marketing

Carcinoma, Transitional Cell